uveal neoplasms

Summary

Summary: Tumors or cancer of the UVEA.

Top Publications

  1. Singh A, Turell M, Topham A. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881-5 pubmed publisher
    ..To determine trends in incidence, treatment, and survival with primary uveal melanoma in the United States over a 36-year period from 1973 to 2008...
  2. Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933-6 pubmed publisher
    ..Resequencing of ten uveal melanomas with disomy 3 that developed metastases identified SF3B1 mutations in three tumors, none of which targeted Arg625. ..
  3. Harbour J, Onken M, Roberson E, Duan S, Cao L, Worley L, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410-3 pubmed publisher
    ..These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target...
  4. Woodman S. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012;18:148-52 pubmed publisher
    ..Much work is now underway to leverage this knowledge to develop effective therapies. This review summarizes recently discovered molecular features of uveal melanoma and therapies being explored to capitalize on this knowledge...
  5. Gravells P, Hoh L, Canovas D, Rennie I, Sisley K, Bryant H. Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R. Br J Cancer. 2011;104:1098-105 pubmed publisher
    ..To investigate why UM are so chemo-resistant we explored the effect of interstrand cross-linking agents mitomycin C (MMC) and cisplatin in comparison with hydroxyurea (HU)...
  6. Mariani P, Servois V, Piperno Neumann S. Therapeutic options in metastatic uveal melanoma. Dev Ophthalmol. 2012;49:166-81 pubmed publisher
    ..Molecular and chromosomal classification strongly predicting metastatic death has to be used to identify genetic profiles and pathways involved in the pathogenesis of uveal melanoma leading to new targeted therapeutic strategies...
  7. Cassoux N, Rodrigues M, Plancher C, Asselain B, Levy Gabriel C, Lumbroso Le Rouic L, et al. Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma. Br J Ophthalmol. 2014;98:769-74 pubmed publisher
    ..This study investigated the capacity of genetic analysis of uveal melanoma samples to identify high-risk patients and discusses its clinical implications...
  8. Thill M, Berna M, Grierson R, Reinhart I, Voelkel T, Piechaczek C, et al. Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res. 2011;21:405-16 pubmed publisher
    ..Further experiments are needed to isolate stem cell marker-positive cells, to evaluate their functional properties and to explore therapeutical approaches to these putative CSCs in uveal melanoma...
  9. Hawkins B. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clin Trials. 2011;8:661-73 pubmed publisher

More Information

Publications62

  1. Abdel Rahman M, Christopher B, Faramawi M, Said Ahmed K, Cole C, McFaddin A, et al. Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma. Mod Pathol. 2011;24:954-62 pubmed publisher
    ..Microsatellite-based genotyping of chromosome 3 is highly sensitive for detection of aggressive uveal melanoma...
  2. Jia R, Jiao Z, Xu X, Wang J, Zhou Y, Song X, et al. Functional significance of B7-H1 expressed by human uveal melanoma cells. Mol Med Rep. 2011;4:163-7 pubmed publisher
    ..This provides new insight into anti-tumor immunity against B7-H1-expressing UM cells...
  3. Griewank K, Murali R, Schilling B, Scholz S, Sucker A, Song M, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 2013;109:497-501 pubmed publisher
    ..Recently, activating mutations in the TERT promoter were identified in cutaneous melanoma. We tested a cohort of ocular melanoma samples for similar mutations...
  4. Krauthammer M, Kong Y, Ha B, Evans P, Bacchiocchi A, McCusker J, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006-14 pubmed publisher
    ..These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit...
  5. Griewank K, Murali R. Pathology and genetics of uveal melanoma. Pathology. 2013;45:18-27 pubmed publisher
    ..In this review, we summarise the clinical, pathological and genetic features of uveal melanoma, with emphasis on recent discoveries...
  6. Couturier J, Saule S. Genetic determinants of uveal melanoma. Dev Ophthalmol. 2012;49:150-65 pubmed publisher
    ..3, coding for a protein promoting cell migration, is highly overexpressed in class 2 tumors. The overall expression signature of class 2 tumors suggests they may originate from neuroectodermal stem cells...
  7. van den Bosch T, Van Beek J, Vaarwater J, Verdijk R, Naus N, Paridaens D, et al. Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci. 2012;53:2668-74 pubmed publisher
  8. Aronow M, Sun Y, Saunthararajah Y, Biscotti C, Tubbs R, Triozzi P, et al. Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. Surv Ophthalmol. 2012;57:463-73 pubmed publisher
    ..FISH is a widely available, versatile technology, and when performed optimally has the potential to be a valuable tool for determining the prognosis of uveal melanoma...
  9. Carbone M, Ferris L, Baumann F, Napolitano A, Lum C, Flores E, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179 pubmed publisher
  10. Coupland S, Lake S, Zeschnigk M, Damato B. Molecular pathology of uveal melanoma. Eye (Lond). 2013;27:230-42 pubmed publisher
    ..The identification of abnormal signalling pathways, genes and proteins in UM opens the way for target-based therapies, improving prospects for conserving vision and prolonging life...
  11. Abdel Rahman M, Pilarski R, Cebulla C, Massengill J, Christopher B, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856-9 pubmed publisher
    ..To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer...
  12. Van den Bosch T, Koopmans A, Vaarwater J, van den Berg M, de Klein A, Verdijk R. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance. Invest Ophthalmol Vis Sci. 2013;54:7354-61 pubmed publisher
    ..To examine the prognostic relevance of expression of the chemokine receptors CCR7 and CXCR4 and its ligand CXCL12 in uveal melanoma in nonmetastatic and metastatic patients with correlation to liver metastasis and overall survival...
  13. Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito A, et al. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. Eur J Cancer. 2013;49:3353-65 pubmed publisher
    ..Cetuximab triggers natural killer (NK) cells to lyse EGFR+ cell lines and to release TNF-?. EGFR appears suited as a novel molecular drug target for therapy of uveal melanoma. ..
  14. Hoh L, Gravells P, Canovas D, Ul Hassan A, Rennie I, Bryant H, et al. Atypically low spontaneous sister chromatid exchange formation in uveal melanoma. Genes Chromosomes Cancer. 2011;50:34-42 pubmed publisher
  15. Wang J, Jia R, Yao Y, Cun B, Huang X, Gu P, et al. Differential expression of Mart-1 in human uveal melanoma cells. Mol Med Rep. 2011;4:799-803 pubmed publisher
    ..5 cells according to Western blot analysis, although OM431 cells had the highest expression of Mart-1 mRNA according to real-time PCR. The results indicate the potential use of Mart-1 in the development of therapy for UM...
  16. Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-9 pubmed publisher
    ..Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas...
  17. Bronkhorst I, Maat W, Jordanova E, Kroes W, Schalij Delfos N, Luyten G, et al. Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med. 2011;135:1042-7 pubmed publisher
    ..Fluorescence in situ hybridization (FISH) analyses on tumor sections and on isolated nuclei showed that even low numbers of cells with monosomy of chromosome 3 adversely affected survival...
  18. Testa J, Cheung M, Pei J, Below J, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-5 pubmed publisher
    ..We hypothesize that other cancers may also be involved and that mesothelioma predominates upon asbestos exposure. These findings will help to identify individuals at high risk of mesothelioma who could be targeted for early intervention...
  19. Furney S, Pedersen M, Gentien D, Dumont A, Rapinat A, Desjardins L, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122-1129 pubmed publisher
    ..SF3B1 encodes a component of the spliceosome, and RNA sequencing revealed that SF3B1 mutations were associated with differential alternative splicing of protein coding genes, including ABCC5 and UQCC, and of the long noncoding RNA CRNDE...
  20. Shields C, Ganguly A, Bianciotto C, Turaka K, Tavallali A, Shields J. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011;118:396-401 pubmed publisher
    ..To determine the relationship between monosomy 3 and incidence of metastasis after genetic testing of uveal melanoma using fine-needle aspiration biopsy (FNAB)...
  21. Ambrosini G, Pratilas C, Qin L, Tadi M, Surriga O, Carvajal R, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18:3552-61 pubmed publisher
  22. Abdel Rahman M, Cebulla C, Verma V, Christopher B, Carson W, Olencki T, et al. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res. 2012;100:26-31 pubmed publisher
    ..These findings should be considered when designing clinical trials testing effectiveness of various therapies of metastatic UM...
  23. Cun B, Song X, Jia R, Zhao X, Wang H, Ge S, et al. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biol Ther. 2012;13:77-84 pubmed publisher
    ..Our study suggests the viro-chemo combination therapy is feasible and is a potentially promising approach for the treatment of uveal melanoma...
  24. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess B, et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012;11:22 pubmed
    ..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2...
  25. Onken M, Worley L, Char D, Augsburger J, Correa Z, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596-603 pubmed publisher
    ..This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk)...
  26. Madic J, Piperno Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res. 2012;18:3934-41 pubmed publisher
    ..To develop a molecular tool to detect circulating tumor-derived DNA (ctDNA) in the plasma from patients with uveal melanoma as a marker of tumor burden and monitor treatment efficacy...
  27. Chen X, Wang J, Shen H, Lu J, Li C, Hu D, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci. 2011;52:1193-9 pubmed publisher
    ..The authors' previous studies on miR-34a showed that miRNA can influence the growth of uveal melanoma cells. In this study, they investigated the role of miR-137 in the pathogenesis of uveal melanoma...
  28. Asnaghi L, Ebrahimi K, Schreck K, Bar E, Coonfield M, Bell W, et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res. 2012;18:654-65 pubmed publisher
    ..To determine whether uveal melanoma, the most common primary intraocular malignancy in adults, requires Notch activity for growth and metastasis...
  29. Bronkhorst I, Vu T, Jordanova E, Luyten G, Burg S, Jager M. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53:5370-8 pubmed publisher
    ..An analysis of the different functional phenotypes of tumor-infiltrating leukocytes (TIL) and a comparison with the genetic background of the tumors may help to explain this apparent anomaly...
  30. Yang C, Wei W. The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 2011;54:351-8 pubmed publisher
    ..The differentially expressed miRNAs may be involved in uveal melanoma pathogenesis, and may help promote the diagnosis and treatment for uveal melanoma...
  31. Landreville S, Lupien C, Vigneault F, Gaudreault M, Mathieu M, Rousseau A, et al. Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization. Mol Vis. 2011;17:1324-33 pubmed
    ..This study attempts to identify changes in the patterns of gene expression that lead to malignant transformation and proliferation of normal uveal melanocytes (UVM) using the Suppressive Subtractive Hybridization (SSH) technique...
  32. Khalili J, Yu X, Wang J, Hayes B, Davies M, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18:4345-55 pubmed publisher
    ..In this study, we test the effect of the clinically relevant small molecule inhibitors GSK1120212 (MEK inhibitor) and GSK2126458 (pan class I PI3K inhibitor) on uveal melanoma cells with different GNAQ/11 mutation backgrounds...
  33. Höiom V, Edsgard D, Helgadottir H, Eriksson H, All Ericsson C, Tuominen R, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer. 2013;52:378-84 pubmed publisher
    ..Such individuals may then be enrolled in preventive programs and regular screenings to facilitate early detection and thereby improve prognosis...
  34. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus H, et al. Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem. 2010;53:8556-68 pubmed publisher
    ..These data demonstrate that dipyrimidine amines are unique CXCR4 antagonists with high potency and specificity...
  35. Thomas S, Pütter C, Weber S, Bornfeld N, Lohmann D, Zeschnigk M. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer. 2012;106:1171-6 pubmed publisher
    ..The strong association of metastatic disease with M3 offers the opportunity for molecular prognostic testing of UM patients...
  36. Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, et al. Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS ONE. 2012;7:e29989 pubmed publisher
    ..These results suggest that mda-9/syntenin is involved in uveal melanoma progression and that it warrants further investigation as a candidate molecular marker of metastases and a potential therapeutic target...
  37. Griewank K, Yu X, Khalili J, Sozen M, Stempke Hale K, Bernatchez C, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2012;25:182-7 pubmed publisher
    ..We report the mutation status of relevant melanoma genes, expression levels of proteins of interest, and DNA fingerprinting of a panel of uveal melanoma cell lines used in the research community...
  38. Sisley K, Doherty R, Cross N. What hope for the future? GNAQ and uveal melanoma. Br J Ophthalmol. 2011;95:620-3 pubmed publisher
    ..Here, the authors review the background to GNAQ in UM and explore what makes it such an interesting target for the future treatment of patients...
  39. Patel M, Smyth E, Chapman P, Wolchok J, Schwartz G, Abramson D, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17:2087-100 pubmed publisher
  40. Dong F, Lou D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537-46 pubmed
    ..Recent studies have revealed that miRNAs function as tumor suppressors or oncogenes. In the present study, we investigated the role of miRNA-34b/c in uveal melanoma...
  41. Harbour J. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012;25:171-81 pubmed publisher
    ..These mutations appear to be key events that provide the potential for targeted therapy. This article will review the genetic findings in uveal melanoma over the past two decades and suggest important areas for future work...
  42. Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71:666-74 pubmed publisher
    ..Our findings suggest that PTP4A3 or its cellular substrates could constitute attractive therapeutic targets to treat metastatic uveal melanomas...
  43. Landreville S, Agapova O, Kneass Z, Salesse C, Harbour J. ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity. Pigment Cell Melanoma Res. 2011;24:430-7 pubmed publisher
    ..These findings suggest that some uveal melanoma cells have greater potential for metastasis than others and that a better understanding of such cells may be necessary for more successful therapies for metastatic melanoma...
  44. Mitsiades N, Chew S, He B, Riechardt A, Karadedou T, Kotoula V, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci. 2011;52:7248-55 pubmed publisher
    ..The impact of B-Raf and MEK inhibitors on G?-mutant UMs remains unknown...
  45. Landreville S, Vigneault F, Bergeron M, Leclerc S, Gaudreault M, Morcos M, et al. Suppression of ?5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2011;24:643-55 pubmed publisher
    ..These uveal melanoma cell lines might therefore prove particularly useful as cellular models to investigate ?5?1 function in the pathogenesis of invasive uveal melanoma...
  46. Field M, Harbour J. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25:234-9 pubmed publisher
    ..To provide an update on the rapidly evolving methods for assessing prognosis and predicting response to targeted molecular therapy in uveal melanoma...
  47. Harbour J, Roberson E, Anbunathan H, Onken M, Worley L, Bowcock A. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45:133-5 pubmed publisher
    ..Thus, uveal melanoma is among a small group of cancers associated with SF3B1 mutations, and these mutations denote a distinct molecular subset of uveal melanomas...
  48. Landreville S, Agapova O, Matatall K, Kneass Z, Onken M, Lee R, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408-16 pubmed publisher
    ..The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM...
  49. Harbour J. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 2009;148:823-9.e1 pubmed publisher
    ..To critically assess the status of molecular prognostic testing and its use for individualized patient care in uveal melanoma...
  50. Babchia N, Calipel A, Mouriaux F, Faussat A, Mascarelli F. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 2008;49:2348-56 pubmed publisher
    ..Uveal melanoma cells express WT B-Raf and only rarely express V600E B-Raf. This study was conducted to investigate the effects of HSP90 inhibition on uveal melanoma cell lines...
  51. Valyi Nagy K, Dosa S, Kovacs S, Bacsa S, Voros A, Shukla D, et al. Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures. Cancer Gene Ther. 2010;17:223-34 pubmed publisher
    ..These findings indicate that 3D tumor cell cultures can be used to identify distinct tumor cell populations with increased resistance to HSV-1 and to explore mechanisms of ECM-mediated tumor resistance to oncolytic virotherapy...
  52. Schmittel A, Schuster R, Bechrakis N, Siehl J, Foerster M, Thiel E, et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005;15:447-51 pubmed
    ..1% versus 47.3%, respectively. Based on the observation of prolonged disease stabilization, we recommend further investigation of the gemcitabine/treosulfan combination with a dose of 3500 mg/m2 of treosulfan in metastatic uveal melanoma...
  53. Singh A, Borden E. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143-50, ix pubmed
    ..In general, the survival with metastatic uveal melanoma is poor, with a median survival of less than 6 months...